HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting

Tissue Antigens

Volumn 64, Issue 3, 2004, Pages 251-256

  Paris, R ^a   Bejrachandra, S ^b   Karnasuta, C ^a   Chandanayingyong, D ^b   Kunachiwa, W ^c   Leetrakool, N ^d   Prakalapakorn, S ^a,h   Thongcharoen, P ^b   Nittayaphan, S ^a   Pitisuttithum, P ^e   Suriyanon, V ^c   Gurunathan, S ^f   McNeil, J G ^g   Brown, A E ^a   Birx, D L ^g   De Souza, M ^a  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d Faculty of Medicine Chiang Mai University   (Thailand)

^e MAHIDOL UNIVERSITY   (Thailand)

^f SANOFI PASTEUR   (France)

^g WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^h EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Canarypox; Cytotoxic T lymphocyte response; Human immunodeficiency virus 1; Human leukocyte antigen

Indexed keywords

CD8 ANTIGEN; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 160; HLA A11 ANTIGEN; HLA A24 ANTIGEN; HLA A33 ANTIGEN; HLA ANTIGEN CLASS 1; HLA B44 ANTIGEN; HLA B46 ANTIGEN; HLA B75 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ACTIVE IMMUNIZATION; ADULT; ARTICLE; CANARYPOX VIRUS VECTOR; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; FEMALE; HLA SYSTEM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THAILAND;

ADULT; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP160; HIV INFECTIONS; HIV-1; HUMANS; MALE; T-LYMPHOCYTES, CYTOTOXIC; THAILAND; VIRAL VACCINES;

CANARYPOX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; STAPHYLOCOCCUS PHAGE 187;

EID: 4344678172     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2004.00270.x     Document Type: Article

References (23)

1. + T-cell approach feasible? Nat Rev Immunol 2002: 2: 283-91.
2. Thomson MM, Perez-Alvarez L, Najera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect Dis 2002: 2: 461-71.
3. Michael NL, Chang G, Louie LG et al. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med 1997: 3: 338-40.
4. Trachtenberg EA, Erlich HA. A review of the role of the human leukocyte antigen (HLA) system as a host immunogenetic factor influencing HIV transmission and course of infection with progression to AIDS. In: Korber B et al., eds. HIV Molecular Immunology Database. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 2001: I-43-60.
5. Trachtenberg E, Korber B, Sollars C et al. Advantage of rare HLA supertype in HIV disease progression. Nat Med 2003: 9: 928-35.
6. Moore CB, John M, James IR et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 2002: 296: 1439-43.
7. Gao X, Nelson GW, Karacki P et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N Engl J Med 2001: 344: 1668-75.
8. Kaslow RA, Rivers C, Tang J et al. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. J Virol 2001: 75: 8681-9.
9. Ferrari G, Neal W, Jones A et al. CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition. Immunol Lett 2001: 79: 37-45.
10. Gelder CM, Lambkin R, Hart KW et al. Associations between human leukocyte antigens and nonresponsiveness to influenza vaccine. J Infect Dis 2002: 185: 114-7.
11. Alper CA, Kruskall MS, Marcus-Bagley D et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 1989: 321: 708-12.
12. Charron D. Genetic diversity of HLA. Functional and medical implications. In: Charron D, ed. France: EDK, 1996.
13. + cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999: 180: 290-8.
14. DiBrino M, Parker KC, Margulies DH et al. Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian population. Biochemistry 1995: 34: 10130-8.
15. Chandanayingyong D, Stephens HA, Klaythong R et al. HLA-A, -B, -DRB1, -DQA1, and -DQB1 polymorphism in Thais. Hum Immunol 1997: 53: 174-82.
16. Macdonald WA, Purcell AW, Mifsud NA et al. A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition. J Exp Med 2003: 198: 679-91.
17. Hossain MS, Tomiyama H, Inagawa T et al. HLA-A*3303-restricted cytotoxic T lymphocyte recognition for novel epitopes derived from the highly variable region of the HIV-1 Env protein. AIDS 2001: 15: 2199-201.
18. The AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag and Pro in combination with rgp120. J Infect Dis 2001: 183: 563-70.
19. Belshe RB, Stevens C, Gorse GJ et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001: 183: 1343-52.
20. Cao H, Kaleebu P, Hom D et al. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J Infect Dis 2003: 187: 887-95.
21. Gupta K, Hudgens M, Corey L et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acguir Immune Defic Syndr 2002: 29: 254-61.
22. Cox JH, de Souza M, Brown AE et al. Comparison of immunogenicity of HIV-1 (ALVAC) between phase II trials conducted in the USA and Thailand. AIDS Vaccine 2003 [Abstract 146].
23. Mori M, Beatty PG, Graves M et al. HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation 1997: 64: 1017-27.